First expirience of adalimumab administration in Russia: preliminary results of an open 24 week study

First expirience of adalimumab administration in Russia: preliminary results of an open 24 week study

Introduction. Adalimumab (Humira) is a monoclonal anti-TNFa antibody fully identical to human antibodies, a member of group of TNFa blockers which are now the main biological drugs for the treatment of rheumatoid arthritis (RA). Till recently adalimumab was little known in Russia. Material and metho...

Full description

Saved in:
Bibliographic Details
Main Authors: E L Luchichina, D E Karateev, E L Nasonov
Format: Article
Language:Russian
Published: IMA PRESS LLC 2008-10-01
Series:Научно-практическая ревматология
Subjects:
adalimumab
rheumatoid arthritis
Online Access:https://rsp.mediar-press.net/rsp/article/view/554
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items